"I'm just 'Thinking outside the square.'" I wonder what happens to all the expertise that has been gathered to develop Duravr if Anteris is taken out by one of the big players. We have a great team of staff, advisory Board members, engineers and others and it would be a shame to see them disbanded if there are other challenges they could address. The following is from the MST report - My thinking outside the square is that Anteris will continue in existence and pursue other opportunities as a structural heart company. Your suggestion of a hook up with 4C Medical might not be the best option for the TAVR project but there could be other opportunities with 4C -
4C Medical Technologies, Inc. is conducting a clinical research study to evaluate the safety and performance of a new device for the treatment of severe mitral regurgitation (MR), AltaValve.
As a minor shareholder I will just tag along for the ride and remain patient.
AVR Price at posting:
$9.40 Sentiment: Buy Disclosure: Held
(20min delay)